ELAN · Elanco Animal Health Inc · Financials
$22.39
-0.22 (-0.97%)
At close · Sep 30
Return incl. dividend (before tax)
Market Cap
$11.15B
Shares
499.62M
Volume · Sep 30
5.36M
Avg daily vol (3M)
6.11M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$4.72B
+6.2%
FY2025
Net Income
-$232M
-168.6%
FY2025
Gross Margin
54.99%
+0.1pp
FY2025
Diluted EPS
-$0.47
-169.1%
FY2025
Operating Cash Flow
$560M
+3.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $5.02B | $4.72B | $4.44BG | $4.42B | $4.41B | $4.76BG | $3.27B | $3.07B | $3.07B | $2.89B | $2.91B | |
| $2.24B | $2.12B | $2B | $1.93B | $1.91B | $2.13B | $1.67B | $1.47B | $1.57B | $1.49B | $1.41B | |
| $2.78B | $2.59B | $2.44B | $2.49B | — | — | — | — | — | — | — | |
| — | 54.99% | 54.88% | 56.28% | — | — | — | — | — | — | — | |
| $371M | $368M | $344M | $327M | $321M | $369M | $329M | $270M | $246.6M | $251.7M | $265.8M | |
| $1.52B | $1.43B | $1.31B | $1.29B | $1.27B | $1.4B | $997M | $760M | $735.2M | $779.8M | $784.8M | |
| $556M | $543M | $527M | $548M | $528M | $556M | $360M | $200M | $197.4M | $221.2M | $170.7M | |
| $693M | $680M | $662M | $694M | $682M | $716M | $517M | $314M | $296M | $318.4M | $254.4M | |
| $157M | $156M | $44M | $0 | -$7M | $110M | $157M | $19.3M | $27.2M | $193.8M | — | |
| — | — | $3.95B | $5.61B | $4.48B | $5.34B | $3.95B | $2.99B | $2.95B | $3.12B | $2.94B | |
| $248M | $220M | $235M | $277M | $241M | $236M | $150M | $79M | $29.6M | $0 | $0 | |
| — | $43M | $31M | $4M | — | — | — | — | — | — | — | |
| -$46M | — | — | -$75M | -$32M | -$5M | $178M | -$28M | -$41.3M | $100K | $2.8M | |
| -$166M | -$224M | $488M | -$1.2B | -$72M | -$571M | -$677M | $78M | $114.1M | -$232.6M | -$22.4M | |
| $33M | $8M | $150M | $36M | $6M | -$88M | -$103M | $10M | $27.6M | $78.1M | $25.5M | |
| -$199M | -$232M | $338M | -$1.23B | -$78M | -$483M | -$574M | $68M | $86.5M | -$310.7M | -$47.9M | |
| — | -4.92% | 7.61% | -27.87% | -1.77% | -10.14% | -17.54% | 2.21% | 2.82% | -10.75% | -1.64% | |
| -$226M | $398M | -$167M | -$1.11B | -$261M | -$995M | -$98M | $117M | $64.8M | -$110.4M | -$282.9M | |
| USD/shares | -$0.41 | -$0.47 | $0.68 | -$2.50 | -$0.16 | -$0.99 | -$1.30 | $0.18 | $0.28 | -$1.06 | — |
| USD/shares | -$0.40 | -$0.47 | $0.68G | -$2.50G | -$0.16 | -$0.99G | -$1.30 | $0.18 | $0.28 | -$1.06 | — |
| shares | — | 496.4M | 494M | 492.3M | 488.3M | 487.2M | 441.4M | 369M | 313.7M | 293.3M | 293.29M |
| shares | — | 496.4M | 497.3M | 492.3M | 488.3M | 487.2M | 441.4M | 370.3M | 313.7M | 293.3M | 293.3M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
3.00×
Peer median 2.88×
EV/EBIT
—
Peer median 20.63×
P/E (TTM)
—
Peer median 17.15×
Peer medians compare against the 29 similar-size Drug Manufacturers - Specialty & Generic companies (of 100 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Reportable Segment | $4,715,000,000 | $4,439,000,000 | $4,417,000,000 | $4,411,000,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Non Us | $2,481,000,000 | $2,403,000,000 | $2,434,000,000 | $2,446,000,000 | $2,640,000,000 | $1,796,000,000 | $1,546,000,000 | $1,583,600,000 |
| United States | $2,234,000,000 | $2,036,000,000 | $1,983,000,000 | $1,965,000,000 | $2,124,000,000 | $1,475,000,000 | $1,525,000,000 | $1,483,200,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Farm Animal | $2,362,000,000 | $2,250,000,000 | $2,271,000,000 | $2,219,000,000 | $2,332,000,000 | $1,835,000,000 | $1,855,000,000 | — |
| Pet Health | $2,300,000,000 | $2,143,000,000 | $2,104,000,000 | $2,138,000,000 | $2,350,000,000 | $1,356,000,000 | $1,136,000,000 | — |
| Cattle | $1,125,000,000 | $1,007,000,000 | $949,000,000 | $944,000,000 | $980,000,000 | — | — | — |
| Poultry | $858,000,000 | $796,000,000 | $765,000,000 | $716,000,000 | $744,000,000 | — | — | — |
| Swine | $379,000,000 | $366,000,000 | $382,000,000 | $384,000,000 | $464,000,000 | — | — | — |
| Contract Manufacturing | $53,000,000 | $46,000,000 | $42,000,000 | $54,000,000 | $82,000,000 | $80,000,000 | $80,000,000 | $93,900,000 |
| Aqua | $0 | $81,000,000 | $175,000,000 | $175,000,000 | $144,000,000 | — | — | — |
| Farm Animal Future Protein and Health | — | — | — | — | — | — | — | $711,200,000 |
| Farm Animal Ruminants and Swine | — | — | — | — | — | — | — | $1,174,000,000 |
| Pet Health Disease Prevention | — | — | — | — | — | — | — | $804,600,000 |
| Pet Health Therapeutics | — | — | — | — | — | — | — | $283,100,000 |
Key facts
CIK
1739104
CUSIP
28414H103
13F (30d)
18 filings
13 filers
Visit website
Investor relations